Bruker Advances Magnet Technology for Broader Adoption of NMR in Academic and Biopharma Research, and Process Analytical Technologies
- None.
- None.
The introduction of Bruker Corporation's Ascend Evo 600 NMR magnet represents a significant advancement in the field of nuclear magnetic resonance technology. The impact on the business landscape, particularly within the biopharma sector, is multifaceted. Firstly, the extended one-year liquid helium hold-time is a notable improvement over traditional models, which typically require more frequent refills. This enhancement not only reduces operational costs but also addresses the global helium shortage by decreasing consumption, which can be a critical factor for research institutions and pharmaceutical companies alike.
Furthermore, the integration of the Fourier 80 platform with the synTQ PAT management software indicates Bruker's commitment to innovation in process analytical technologies. This move aligns with the industry's trend towards real-time monitoring and quality control, which is essential for the optimization of manufacturing processes. The ability to synchronize multiple analytical techniques and gather comprehensive data streams is likely to improve the efficiency and reliability of API production, thereby potentially reducing time-to-market for new drugs.
From a market perspective, Bruker's advancements could lead to increased adoption of NMR technology, especially in distributed manufacturing settings where on-demand production is becoming more prevalent. This could open up new revenue streams for Bruker and strengthen its position in the market.
Bruker's novel NMR magnet technology and analytical solutions are poised to have a significant impact on the biopharma industry, particularly in the areas of drug discovery, development and manufacturing. The Ascend Evo 600's reduced installation and operational costs, along with its sustainability features, make it an attractive option for companies looking to invest in high-quality NMR systems. The implications for stakeholders are considerable, as the technology can streamline the drug development process by providing advanced characterization of biologics and new drug modalities.
Moreover, the integration of NMR with AI machine learning for process optimization is a forward-thinking approach that aligns with the industry's drive towards smart manufacturing. The ability to enhance flow chemistry with real-time data analytics and control can lead to safer, more efficient and environmentally friendly production methods. Such innovations could give companies a competitive edge, fostering a shift towards more agile and responsive pharmaceutical production models.
ASILOMAR, Calif.--(BUSINESS WIRE)-- Bruker Corporation (Nasdaq: BRKR), the leading provider of nuclear magnetic resonance (NMR) systems, today announces novel magnet technology and analytical solutions to support broad adoption of NMR in academic basic and clinical research, as well as in biopharma drug discovery, development and process analytical technologies (PAT).
Ascend Evo 600 NMR magnet with a 1-year liquid helium hold-time (Photo: Business Wire)
At the 65th ENC (www.enc-conference.org), Bruker introduces the Ascend Evo 600, a novel compact 54 mm standard-bore 14.1 Tesla (600 MHz) NMR magnet, which features a full one-year liquid Helium hold-time, more than doubling refill intervals. The Ascend EvoTM 600 is the latest addition to the Evo magnet series, which includes compact 1 GHz, 900 MHz, 500 MHz, and 400 MHz magnets operating at 4.2 K, employing advanced superconducting magnet coil and cryogenic technology. The new Ascend Evo 600 magnet is easier to site, has reduced installation and operational costs, and has lower Helium consumption compared to previous 600 MHz magnets.
Importantly, it features an unprecedented, more than doubled one-year Helium hold-time for easier lab deployment, less maintenance, and further improved sustainability. With the Ascend Evo series, Bruker makes NMR more accessible to researchers across various fields, from clinical metabolism research to the biopharma industry, enabling advanced characterization of biologics and new drug modalities.
In addition, Bruker expands the applications of its Fourier 80 platform, a benchtop 80 MHz Fourier Transform NMR with a high-performance permanent magnet that requires no cryogens or power. The Fourier 80 can now be integrated with synTQTM PAT management software for synchronization with sensors and other analytical techniques, such as IR or Raman spectroscopy, for multiple, integrated data streams that provide more comprehensive process analysis and quality control. The Fourier PAT solution reduces tedious calibrations and enhances (bio)process control by providing a wealth of structural information, selectivity, and direct quantification in lab or manufacturing settings.
The Fourier PAT solution can be deployed in distributed manufacturing of Active Pharmaceutical Ingredients (APIs). Here, the Fourier 80 system gathers reaction data for AI machine learning to formulate the rules and actions to guide process optimization.
Mr. Philippe Robin, Founder and CEO of Alysophil, commented: “This PAT setup is game-changing in the way we produce APIs, enabling distributed manufacturing and on-demand production. Coupling the PAT module with our AI agent in our API manufacturing unit enhances the advantages that accompany flow chemistry, such as increased safety, reduced environmental footprint and better economics.”
About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240408534756/en/
Investor Contact:
Justin Ward
Sr. Director, Investor Relations & Corporate Development
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com
Media Contact:
Markus Ziegler
Sr. Director and Head of Group Marketing
Bruker BioSpin
T: +49 172 3733531
E: pr@bruker.com
Source: Bruker Corporation
FAQ
What is the latest NMR magnet introduced by Bruker ?
What are the key features of the Ascend Evo 600 NMR magnet?
How does the Fourier 80 platform enhance process analysis in API manufacturing?
What benefits does the Fourier PAT solution offer in API manufacturing?
Who commented on the game-changing nature of the PAT setup in API production?
